Associated Papers
An overview of BAP1 biological functions and current therapeutics.
Elsayed AM et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2025
Prevalence of Individuals With Multiple Diagnosed Genetic Diseases in the Undiagnosed Diseases Network.
Gimeno AF et al.
American Journal of Medical Genetics. Part A, 2025
Saturation genome editing of BAP1 functionally classifies somatic and germline variants.
Waters AJ et al.
Nature Genetics, 2024
BRCA1-associated protein 1: Tumor predisposition syndrome and Kury-Isidor syndrome, from genotype-phenotype correlation to clinical management.
West EC et al.
Clinical Genetics, 2024
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
Thomas JF et al.
Science Advances, 2023
37556531 (PubMed )
Supplement: sciadv.adg9832_sm.pdf
Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1.
Thomas JF et al.
Biorxiv : the Preprint Server for Biology, 2023
36865140 (PubMed )
Supplement: NIHPP2023.02.23.529554v1-supplement-1.pdf
Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.
Denisova E et al.
Cancer Gene Therapy, 2022
34045664 (PubMed )
Supplement: 41417_2021_347_MOESM4_ESM.xls › C000-JMUDMJ
Proteomic analysis identifies novel binding partners of BAP1.
Baas R et al.
Plos One, 2021
Phase and context shape the function of composite oncogenic mutations.
Gorelick AN et al.
Nature, 2020
32461694 (PubMed )
Supplement: NIHMS1582596-supplement-1582596_Supp_Tab1-5.xlsx › Table_S2._Composite_mutations
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F et al.
Oncotarget, 2015
26452128 (PubMed )
Supplement: oncotarget-06-32161-s002.xls › Predictions
Select a paper to view details